UK markets open in 30 minutes

HYLORIS PHARMA. S.A. (52U.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
15.200.00 (0.00%)
As of 4:33PM CEST. Market open.
Full screen
Previous close15.20
Open15.25
Bid0.00 x N/A
Ask0.00 x N/A
Day's range15.20 - 15.25
52-week range9.00 - 15.25
Volume600
Avg. volume16
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Hyloris Announces Approval of Maxigesic® IV in the UK and Ireland

    Maxigesic® IV provides a non-opioid, dual mode-of-action pain management alternative to traditional analgesics Liège, Belgium – 19 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces further extension of the European footprint of Maxigesic® IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatm

  • Globe Newswire

    Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome

    Potential to revolutionise the current treatment paradigm and become the cornerstone therapy for patients with suspected acute coronary syndromeEnables accelerated development of HY-073 (IV acetylsalicylic acid), bringing the anticipated FDA submission date forward to end 2023Initially targeting a total addressable patient population of ~2 million in the U.S. Liège, Belgium – 13 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to address

  • Globe Newswire

    Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure

    Patient-friendly alternative to continuous IV administration – proven safety and efficacyTargeting orphan, late-stage heart failure indication with high unmet medical needs Liège, Belgium – 8 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has acquired the global rights from the Baker Heart and Diabetes Institute (“the Baker Institute”),